For the past two decades, Josh Makower, MD, has sat on the innovator’s side of the table creating innovations and innovators through his work with the Exploramed incu-bator and Stanford Biodesign Program. Now, Makower takes his considerable abilities to New Enterprise Associates, where he’ll invest in medtech companies on behalf of one of the indus-try’s most venerable firms. Hear where he sees opportunity and how Astronaut Steve Austin in-fluenced his career path.

Jason Lettman, partner at Lightstone Ventures, set up shop in Ireland after Lightstone closed its debut fund. Hear how he views Medtech from the other side of the Atlantic.

Oculeve, a stealthy start-up with backing from Kleiner, NEA and Versant, opted to sell its neurostim treatment for Dry Eye to Ophthalmology Leader Allergan.

Solace Therapeutics CEO Bill Gruber hopes to repeat the successful exit he helped execute when Hologic paid close to $300 million for his previous company Interlace.

Oxford’s Scott Defelice explains how his company and 3D printing will impact medtech.

Geoff Gurtner, MD, managing partner of TauTona Group, is trying to look differently at how Medtech is created, funded and sold.

Analysts Michael Lachman and Larry Haimovich put down their pens and pick up the mics to discuss the more promising ophthalmology technologies.

Mark Leahey of the MDMA explains how a move against patent troll could cut the legs out from Medtech entrepreneurs and VCs dependent upon IP protection.

Hanson Gifford of The Foundry reviews the evolving challenges behind Medtech innovation and shares details on Fire1 and Ardian.

Matt Hermann, Senior Managing Director of Ascension Ventures, details how Pro-viders and Payer-sponsored investment firms have grown into influential investors in health care.